VHLL sirna

VHLL siRNA (Human)

Cat. Num. AAA8212988

• Gene Names: VHLL; VLP; VHLP
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: VHLL; VHLL siRNA (Human); VLP; Von Hippel-Lindau-like protein; VHL-like protein; VHLL sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: VHLL siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 139

• Applicable Applications for VHLL sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human VHLL gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for VHLL sirna

siRNA to inhibit VHLL expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 51972218
• NCBI GeneID: 391104
• NCBI Accession #: NP_001004319.1
• NCBI GenBank Nucleotide #: NM_001004319.2
• UniProt Accession #: Q6RSH7; A1L4M4
• Molecular Weight: 15,781 Da
• NCBI Official Full Name: von Hippel-Lindau-like protein
• NCBI Official Synonym Full Names: von Hippel-Lindau tumor suppressor-like
• NCBI Official Symbol: VHLL
• NCBI Official Synonym Symbols: VLP; VHLP
• NCBI Protein Information: von Hippel-Lindau-like protein
• UniProt Protein Name: Von Hippel-Lindau-like protein
• Protein Family: Von Hippel-Lindau-like protein
• UniProt Gene Name: VHLL
• UniProt Synonym Gene Names: VLP; VHL-like protein; VLP
• UniProt Entry Name: VHLL_HUMAN

NCBI Description

Von Hippel-Lindau (VHL) tumor suppressor protein is a component of an E3 ubiquitin ligase complex that selectively ubiquitinates the alpha subunit of the hypoxia-inducible factor (HIF) transcription factor for proteasome-mediated degradation. Inactivation of VHL causes VHL disease and sporadic kidney cancer. This gene encodes a VHL homolog that lacks one of two key domains necessary for VHL function. This gene may contribute to the regulation of oxygen homeostasis and neovascularization during placenta development. This gene is intronless, and can also be interpreted as a retrotransposed pseudogene of the VHL locus located on chromosome 3. However, the protein is represented in this RefSeq due to evidence in PMID:14757845 that strongly suggests it is translated. The same publication also indicates that this protein binds HIF alpha but fails to recruit the E3 ubiquitin ligase complex, and it therefore functions as a dominant-negative VHL protein and a protector of HIF alpha. [provided by RefSeq, Jan 2010]

Uniprot Description

VHLL: Functions as a dominant-negative VHL to serve as a protector of HIFalpha.

Protein type: Ubiquitin conjugating system

Chromosomal Location of Human Ortholog: 1q22